Caribou Biosciences, Inc. CRBU shares ended the last trading session 45.6% higher at $5.94. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
If you want to know who really controls Caribou Biosciences, Inc. (NASDAQ:CRBU), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the ...
A look at the shareholders of Caribou Biosciences, Inc. (NASDAQ:CRBU) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 60% ownership ...
To be notified if a class action against Caribou Biosciences, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney ...
Caribou Biosciences, Inc. announced a strategic shift focusing on its lead oncology programs, CB-010 and CB-011, involving workforce and cost reductions aimed at extending its cash runway into the ...
Caribou Biosciences, Inc. Class Action: Levi & Korsinsky Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBU ...
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that Rachel Haurwitz, Ph.D., Caribou’ ...
Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of it ...
Caribou Biosciences, Inc. 競合他社・同業他社分析 - Life Sciences セクター
Our AI model demonstrates 59% historical accuracy for CRBU predictions, based on advanced machine learning algorithms trained on over 10 years of market data.